All updates
All updates
today 48中文产业新闻精选Chinese source评分4747 社区讨论（Reddit）精选评分5959 Invivyd Conference Call Replay: Updates on LIBERTY VYD2311 Monoclonal Antibody Trials
社区讨论（Reddit）评分5555 A single-dose adenovirus-vectored rabies vaccine (ChAdOx2 RabG) was safe and produced strong antibody responses in Tanzanian adults and children. After 1 year, antibody levels remained above the protection threshold and exceeded those from licensed rabies vaccines
社区讨论（Reddit）精选评分7878 NEW RETATRUTIDE DATA: 12 mg barely beat 9 mg, and more people quit on 9 mg than 12 mg. What's going on?
顶刊论文（社媒热度）精选评分7373 Phase 3 Trial of Weekly Oral Islatravir-Lenacapavir for HIV-1 Treatment.
中文产业新闻Chinese source评分2121 诺和诺德启动zenagamtide（司美格鲁肽）I期临床试验，针对2型糖尿病、肥胖及超重人群
中文产业新闻Chinese source评分1717 西比曼生物科技启动C-CAR168治疗难治性系统性硬化症的1b期临床试验
medRxiv Oncology评分3333 Effectiveness of a Molecular Tumor Board in Making Personalized Treatment Recommendations for Patients with Advanced Cancer
中文产业新闻Chinese source评分1717 礼来EloraTZP（替尔泊肽/胰淀素受体激动剂组合）2b期达主要终点，将进入3期临床
中文产业新闻Chinese source评分6666 礼来在2026 EASD公布orforglipron对比甘精胰岛素心血管安全性3期ACHIEVE-4结果
中文产业新闻Chinese source评分5757 礼来在2026 EASD公布eloralintide与替尔泊肽联合治疗EloraTZP 2b期48周减重结果
中文产业新闻Chinese source评分5555 礼来小分子 GLP-1 心血管试验 MACE-4 降低 16%，达非劣效未达优效
中文产业新闻Chinese source评分5656 礼来Eloralintide联合替尔泊肽48周减重23.3%，停药率27%
监管与产业动态评分2929 Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 - Fierce Biotech
监管与产业动态评分2424 Patient death in BMS pulmonary fibrosis trial raises questions, but analysts unshaken - Fierce Biotech
监管与产业动态评分1818 Taiho scores phase 3 win with oral cancer combo for AML-causing blood disorders - Fierce Pharma
监管与产业动态评分4343 Lilly gives deeper glimpse at Foundayo's heart-helping odds in diabetes, obesity phase 3 - Fierce Pharma
监管与产业动态评分5757 New investigational drug delivers up to 23.3% weight loss in people with obesity and diabetes
监管与产业动态评分4040 Autonomous AI could create capacity for thousands more dermatology appointments, real-world study finds
监管与产业动态评分7575 New triple agonist drug produces substantial weight loss in diabetic patients
监管与产业动态精选评分7272 Novel treatment combination improves progression-free survival in most common form of metastatic breast cancer
专家解读（YouTube）评分5757 Insights into the potential of nuvisertib plus momelotinib in patients with myelofibrosis and anemia
专家解读（YouTube）精选评分7171 Liver Cancer Awareness Month: updates in treatment strategies and modalities
社区讨论（Reddit）精选评分8888 Phase 3 results for Retatrutide
社区讨论（Reddit）评分4141 Hang in there! Help is on the way!
社区讨论（Reddit）评分8787 Retatrutide, a triple hormone receptor agonist, for treatment of obesity | TRIUMPH-1 phase 3 clinical trial results show average patient lost 30% of body weight at 104 weeks on highest dose
中文产业新闻Chinese source评分1616 2026 EASD口头报告｜恒瑞医药GLP-1/GIP双受体激动剂瑞普泊肽注射液治疗肥胖合并PMOS Ⅱ期研究亮相
BioPharma Dive精选评分5757 Pfizer’s eczema drug clears skin in mid-stage trial
BioSpace评分3838 Sarepta could be ‘potential turnaround story’ with catalysts lined up into 2027
顶刊论文（社媒热度）评分6161 Effects of semaglutide on kidney disease in type 2 diabetes: a randomized placebo-controlled trial.
BioSpace精选评分6464 Kailera, Hengrui’s GLP-1/GIP candidate delivers weight, menstrual benefits to women with PMOS
中文产业新闻精选Chinese source评分6161 48周减重近20%，奥莱泊肽Ⅲ期LIGHTEN研究亮相EASD 2026
监管与产业动态精选评分6363 Lilly differentiates again in amylin race
Cancer Discovery评分5757 [ 18 F]RCCB6 PET/CT in Diagnosing Clear-Cell Renal Cell Carcinomas: A Prospective Comparison Study with [ 18 F]FDG PET/CT and Conventional Imaging
Cancer Discovery评分5757 Pan-RAS Inhibitor Shows Activity in Advanced Lung Cancer
中文产业新闻Chinese source评分5151 礼来eloralintide联用Mounjaro在糖尿病患者中减重达23%
中文产业新闻Chinese source评分5959 survodutide SYNCHRONIZE-2三期研究：肥胖合并2型糖尿病患者体重降幅最高达13.1%
监管与产业动态评分1717 Signal or noise? > Zealand's stock slides as Boehringer-partnered obesity drug underwhelms again in phase 3 >> Comment below! #strategy #competitiveintelligence #marketing #biotech #pharma #competitivemarketing #healthcare #pharmaceutical
顶刊论文（社媒热度）精选评分6969 Survodutide Once Weekly in Adults with Obesity and Type 2 Diabetes.
顶刊论文（社媒热度）评分4444 8 weeks versus 12 weeks of sofosbuvir-velpatasvir for treatment-naive, non-cirrhotic, chronic hepatitis C (RESOLVE): a multicentre, open-label, non-inferiority, randomised controlled trial in India.